Gilead

HOOKIPA Pharma Reports Third Quarter 2023 Financial Results and Recent Business Highlights

Retrieved on: 
목요일, 11월 9, 2023
Hepatocyte, Prostate-specific antigen, Research, Trial of the century, IND, PSA, Infection, Hepatitis, Pembrolizumab, Head, HIV, Liver, KRAS, Arenavirus, Prostate cancer, Gilead Sciences, Journal, CPI, Development, Gilead, Lung, PAP, Oncology, Serum, Safety, European Society of Gynaecological Oncology, Cancer, Patient, Administration, HBV, The Journal of Infectious Diseases, Investigational New Drug, Pharmaceutical industry, Clothing, Vaccine, Reinsurance

With these encouraging data, we are busy finalizing plans for the randomized trial expected to begin next year,” said Joern Aldag, Chief Executive Officer at HOOKIPA Pharma.

Key Points: 
  • With these encouraging data, we are busy finalizing plans for the randomized trial expected to begin next year,” said Joern Aldag, Chief Executive Officer at HOOKIPA Pharma.
  • Enrollment continued in the ongoing Phase 1/2 study ( NCT05553639 ) of HB-300 for the treatment of advanced prostate cancer.
  • HB-300 is an arenaviral immunotherapy that targets two well-defined self-antigens of prostate cancer, prostatic acid phosphatase (PAP) and prostate-specific antigen (PSA).
  • The decrease was primarily attributable to cash used in operating activities, partly offset by funds resulting from the follow-on financing in June 2023.

Gritstone bio Reports Third Quarter 2023 Financial Results and Provides Corporate Updates

Retrieved on: 
수요일, 11월 8, 2023
PCV, SLATE, CORAL, FDA, Biomedical Advanced Research and Development Authority, Research, IND, Gritstone bio, NCI, Food, Health, Infection, Vaccine, Human services, National Institutes of Health Clinical Center, Administration for Strategic Preparedness and Response, HIV, Gates, BARDA, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, United States Department of Health and Human Services, Administration, Development, Gilead, NAB, Clinical trial, COVID-19, National Cancer Institute, Messenger, Collaboration, Immunotherapy, Safety, Office of Inspector General, U.S. Department of Health and Human Services, Cancer, CEPI, Chemistry, Patient, Pharmaceutical industry, Gritstone, LNP

EMERYVILLE, Calif., Nov. 08, 2023 (GLOBE NEWSWIRE) -- Gritstone bio, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company working to develop the world’s most potent vaccines, today reported financial results for the third quarter ended September 30, 2023 and provided recent corporate and clinical updates.

Key Points: 
  • In oncology, preliminary findings from the randomized Phase 2/3 study of our personalized cancer vaccine, GRANITE, in MSS-CRC are rapidly approaching.
  • The scientific bedrock of GRANITE extends to SLATE, where our collaboration with Steven A. Rosenberg and the NCI is now advancing.
  • Gritstone met its enrollment target of 100 patients randomized in August 2023.
  • An IND to run a Phase 1 study was cleared by the U.S. Food and Drug Administration (FDA) in October 2023.

T-cell Therapy Market Size to Grow USD US$ 76.6 billion from 2023-2033 | Says Transparency Market Research Inc.

Retrieved on: 
월요일, 11월 6, 2023
Acute lymphoblastic leukemia, FDA, Research, CAR, Tisagenlecleucel, Bristol Myers Squibb, Gilead, Growth, Disease, Canadian Aviation Regulations, Infection, Cancer, Patient, B-cell lymphoma, Pharmaceutical industry, Vaccine, Biotechnology, Lisocabtagene maraleucel

WILMINGTON, DEL., Nov. 6, 2023 /PRNewswire/ --The global T cell therapy market was estimated to have acquired US$ 5.3 billion in 2022. It is anticipated to register a 27.9% CAGR from 2023 to 2033 and by 2033, the market is likely to gain US$ 76.6 billion.Expanding the infrastructure for T cell therapy administration, such as specialized treatment centers and healthcare provider training, can enhance patient access and outcomes.

Key Points: 
  • Research and clinical trials are exploring the use of T cell therapy in various disease indications beyond cancer, including autoimmune diseases, infectious diseases, and solid tumors.
  • Global Market for T Cell Therapy: Regional Outlook
    Various reasons are propelling the growth of the T cell therapy market in different regions.
  • The regions include,
    Biotech companies, academic institutions, and pharmaceutical firms in Europe have been investing in T cell therapy research and development.
  • Breyanzi is the second CAR T cell therapy to be approved by the FDA for the treatment of LBCL.

LUNGevity Foundation Unveils New Awareness Video Campaign

Retrieved on: 
목요일, 11월 2, 2023
Linda, Regeneron Pharmaceuticals, Lung cancer, Sanofi, Gilead, Disease, AstraZeneca, Social media, Survivor, Research, Pharmaceutical industry

WASHINGTON, Nov. 2, 2023 To kick off activities recognizing Lung Cancer Awareness Month in November, LUNGevity Foundation, the nation's leading lung cancer-focused nonprofit organization, today launched its new educational video and social media campaign.

Key Points: 
  • WASHINGTON, Nov. 2, 2023 To kick off activities recognizing Lung Cancer Awareness Month in November, LUNGevity Foundation, the nation's leading lung cancer-focused nonprofit organization, today launched its new educational video and social media campaign.
  • "Through the individual stories featured in this campaign, we want to show that there is no one face of lung cancer," said Linda Wenger, Chief Marketing Officer at LUNGevity Foundation.
  • "LUNGevity is transforming how lung cancer is diagnosed and treated, so that more people can thrive like the survivors showcased in our video."
  • This year's educational video campaign received support from AstraZeneca, Sanofi, as well as Gilead and Regeneron.

Aiolos Bio Launches with $245 Million Series A Investment to Advance Development of Novel, Phase 2-Ready TSLP Antibody

Retrieved on: 
화요일, 10월 24, 2023
Science, Other Science, Biotechnology, Research, Pharmaceutical, General Health, Health, Other Health, CSU, FDA, Hives, Atlas Venture, Bio, Roflumilast, Injection, Rheumatoid arthritis, IPF, Gilead Sciences, RA, Drug development, Senior, Pharmacokinetics, Gilead, Caregiver, Partnership, Asthma, Roche, Genentech, Safety, Therapy, Immunology, Patient, Atlas, COPD, TSLP, Pharmaceutical industry, Aeolus

Aiolos launches with an oversubscribed $245 million Series A investment co-led by Atlas Venture, Bain Capital Life Sciences, Forbion, and Sofinnova Investments with additional investment from RA Capital Management (collectively the “Investor Group”).

Key Points: 
  • Aiolos launches with an oversubscribed $245 million Series A investment co-led by Atlas Venture, Bain Capital Life Sciences, Forbion, and Sofinnova Investments with additional investment from RA Capital Management (collectively the “Investor Group”).
  • The Company will advance its lead drug candidate, AIO-001, into a Phase 2 clinical trial in moderate-to-severe asthma patients and is actively evaluating additional development opportunities.
  • AIO-001 is an anti-thymic stromal lymphopoietin (TSLP) monoclonal antibody that has the potential to be administered only twice per year due to its differentiated potency and long half-life.
  • Aiolos Bio acquired exclusive rights for global development and commercialization of the drug outside of greater China from Jiangsu Hengrui Pharmaceuticals Co., Ltd (“Hengrui”) in August 2023.

Patients Suffer as Pfizer Pockets Profits, says AHF

Retrieved on: 
토요일, 10월 21, 2023
AIDS, Public Policy, Government, Health, Infectious Diseases, Advocacy Group Opinion, General Health, Pharmaceutical, AIDS Healthcare Foundation, COVID-19, Big Pharma, Public, Pfizer, Gilead, AHF, Risk, Patient, Pharmaceutical industry

The AIDS Healthcare Foundation (AHF) rebuked pharmaceutical giant Pfizer today for announcing that it plans to charge $1,400 for a five-day course of the COVID-19 antiviral drug Paxlovid.

Key Points: 
  • The AIDS Healthcare Foundation (AHF) rebuked pharmaceutical giant Pfizer today for announcing that it plans to charge $1,400 for a five-day course of the COVID-19 antiviral drug Paxlovid.
  • “This is yet another example of rampant drug profiteering off the backs of sick people by Big Pharma.
  • So that Pfizer can squeeze as much money out of health plans and the pockets of the uninsured as possible for its shareholders and executives,” said AHF President Michael Weinstein.
  • These patients are already likely to face higher treatment costs due to hospitalizations and prolonged treatment and recovery periods.

Black Diamond Therapeutics Announces CEO Transition

Retrieved on: 
월요일, 9월 18, 2023
Diamond, Yale New Haven Hospital, Gilead Sciences, Yale University, Executive, Senior, G1 Therapeutics, ARCH Venture Partners, Senior advisor, Food and Drug Administration, Cancer, Black Diamond, Washington University in St. Louis, Gilead, Patient, Chairperson, Drug discovery, Faculty, Growth, CGI, FDA, Leukemia, IND, Food, Corporate development, Pharmaceutical industry, Nursing, G1

CAMBRIDGE, Mass. and NEW YORK, Sept. 18, 2023 (GLOBE NEWSWIRE) -- Black Diamond Therapeutics, Inc. (Nasdaq: BDTX), a clinical-stage precision oncology company developing therapies that target families of oncogenic mutations in patients with genetically defined cancers, announced that current Chairman of the Board, Mark Velleca, M.D., Ph.D., has been appointed as Chief Executive Officer (CEO) effective immediately. Dr. Velleca succeeds Company CEO and co-founder, David M. Epstein, Ph.D., who has stepped down and will continue to serve on the Board of Directors of the Company.

Key Points: 
  • and NEW YORK, Sept. 18, 2023 (GLOBE NEWSWIRE) -- Black Diamond Therapeutics, Inc. (Nasdaq: BDTX), a clinical-stage precision oncology company developing therapies that target families of oncogenic mutations in patients with genetically defined cancers, announced that current Chairman of the Board, Mark Velleca, M.D., Ph.D., has been appointed as Chief Executive Officer (CEO) effective immediately.
  • Dr. Velleca succeeds Company CEO and co-founder, David M. Epstein, Ph.D., who has stepped down and will continue to serve on the Board of Directors of the Company.
  • Prior to joining the Black Diamond Board, Dr. Velleca served as CEO of G1 Therapeutics, Inc. (Nasdaq: GTHX).
  • Most recently, Dr. Velleca was CEO of StrideBio, a gene therapy company, and a Venture Partner at Hatteras Venture Partners.

Pliant Therapeutics Appoints Minnie Kuo as Chief Development Officer

Retrieved on: 
금요일, 9월 15, 2023
Translation, University of California, San Diego Performance-Based Skills Assessment, Gilead Sciences, Nektar, Biotechnology, University, Therapy, Biochemistry, Senior, Nektar Therapeutics, Bachelor of Arts, ICON, Inflammation, Genentech, Trial of the century, Gilead, Fibrosis, Patient, SAN, Pharmaceutical industry

SOUTH SAN FRANCISCO, Calif., Sept. 15, 2023 (GLOBE NEWSWIRE) -- Pliant Therapeutics, Inc. (Nasdaq: PLRX), a clinical stage biotechnology company focused on discovering and developing novel therapeutics for the treatment of fibrosis, today announced the appointment of Ms. Minnie Kuo as Chief Development Officer.

Key Points: 
  • SOUTH SAN FRANCISCO, Calif., Sept. 15, 2023 (GLOBE NEWSWIRE) -- Pliant Therapeutics, Inc. (Nasdaq: PLRX), a clinical stage biotechnology company focused on discovering and developing novel therapeutics for the treatment of fibrosis, today announced the appointment of Ms. Minnie Kuo as Chief Development Officer.
  • “Minnie is an accomplished biopharmaceutical leader who brings extensive clinical development and cross-functional portfolio management experience to Pliant,” said Bernard Coulie, M.D., Ph.D., President and Chief Executive Officer at Pliant.
  • Prior to joining Pliant, Ms. Kuo held roles of increasing responsibilities at Vir Biotechnology, most recently serving as Senior Vice President of Translational and Clinical Development Operations.
  • In this role, Ms. Kuo served as the operational officer to the Chief Medical Officer, overseeing business operations, clinical operations, and organizational planning across the entire clinical portfolio.

Tentarix Biotherapeutics Completes Series B Financing Bringing Total Equity and Upfront Deal Consideration to $132 Million

Retrieved on: 
수요일, 9월 6, 2023
Research, Engineering, Manufacturing, Biotechnology, Health, Pharmaceutical, General Health, Science, Oncology, Gilead, Gilead Sciences, Protalix BioTherapeutics, Partnership, Series, Pharmaceutical industry

Tentarix Biotherapeutics, a biotechnology company focused on leveraging its proprietary Tentacles™ platform to discover and develop multi-functional, conditional protein therapeutics, today announced it has raised $35 million in a Series B financing led by Amplitude Ventures with participation from Gilead Sciences, Inc., and founding investors Versant Ventures and Samsara BioCapital.

Key Points: 
  • Tentarix Biotherapeutics, a biotechnology company focused on leveraging its proprietary Tentacles™ platform to discover and develop multi-functional, conditional protein therapeutics, today announced it has raised $35 million in a Series B financing led by Amplitude Ventures with participation from Gilead Sciences, Inc., and founding investors Versant Ventures and Samsara BioCapital.
  • “With the support of this group of industry-leading investors, we are well-capitalized to continue advancing our promising Tentacles™ platform,” said President and CEO Paul Grayson.
  • “This financing, combined with our recently announced collaboration with Gilead, extends our cash runway and enables us to expand our pipeline of cell-specific, conditionally active multifunctional biologics that have the potential to tackle previously undruggable targets.”
    “Amplitude believes that multifunctional biologics enable more powerful therapeutic approaches, and we are convinced that Tentarix’s unique technology platform leads the industry," said Amplitude’s Allyson Tighe, who joined Tentarix’s board in connection with the Series B financing.
  • "We’re excited to be working with this exceptional management team and investor syndicate to further advance this work and to enable meaningful therapies for patients.”
    Since inception, Tentarix has now brought in $132 million in capital from equity and upfront partnership payments.

MacroGenics Announces Achievement of $15 Million Milestone Related to Gilead’s Nomination of a Bispecific Research Program

Retrieved on: 
화요일, 9월 5, 2023
Bispecific monoclonal antibody, Monoclonal antibody, Gilead Sciences, Therapy, CD3, Cancer, Macrogen, Research, Gilead, GILD, CD123, Pharmaceutical industry, MD

This nomination grants Gilead an exclusive option, upon achievement of a pre-defined preclinical milestone, to license worldwide rights to the research program.

Key Points: 
  • This nomination grants Gilead an exclusive option, upon achievement of a pre-defined preclinical milestone, to license worldwide rights to the research program.
  • Under the October 2022 agreement, MacroGenics will receive $15 million related to the nomination of a bispecific research program to be conducted by MacroGenics and funded by Gilead.
  • Pursuant to this agreement, which covers MGD024, an investigational, bispecific antibody that binds CD123 and CD3 using MacroGenics’ DART platform, and up to two additional bispecific research programs, MacroGenics remains eligible to receive up to $1.7 billion in target nomination, option fees, and development, regulatory and commercial milestones.
  • MacroGenics will also be eligible to receive tiered, double-digit royalties on worldwide net sales of MGD024 and a flat royalty on worldwide net sales of products under the two research programs.